Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Published byNorman Fox Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United."— Presentation transcript:

1 Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States  Jennifer Taylor-Cousar, Minoo Niknian, Geoffrey Gilmartin, Joseph M. Pilewski  Journal of Cystic Fibrosis  Volume 15, Issue 1, Pages (January 2016) DOI: /j.jcf Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

2 Fig. 1 Change from baseline in percent predicted FEV1 and weight. Panels A and C: mean change. Panel B, individual patient responses. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Download ppt "Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United."

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan 

Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation  Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation  Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,
The prevalence of “risky behaviour” in adults with cystic fibrosis

The prevalence of “risky behaviour” in adults with cystic fibrosis
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,
CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype  Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.

CFTR mutation in an Arab patient: Clinical and functional features of 875+1G→A/875+1G→A genotype  Elide Spinelli, Manuela Seia, Paola Melotti, Eleonora.
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function  Fredrick Van Goor, Haihui Yu, Bill.

Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function  Fredrick Van Goor, Haihui Yu, Bill.
Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Use of high-dose ibuprofen in a pediatric cystic fibrosis center
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Abaigeal D. Jackson, Christopher H. Goss  Journal of Cystic Fibrosis 

Abaigeal D. Jackson, Christopher H. Goss  Journal of Cystic Fibrosis 
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 

H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.

Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation  Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 

Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Cirrhosis and other liver disease in cystic fibrosis

Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
John Widger, Sarath Ranganathan, Philip J. Robinson 

John Widger, Sarath Ranganathan, Philip J. Robinson 
The ease of breathing test tracks clinical changes in cystic fibrosis

The ease of breathing test tracks clinical changes in cystic fibrosis

Similar presentations

Ads by Google